trending Market Intelligence /marketintelligence/en/news-insights/trending/18fe8rrcvafk_3dm8ofnvg2 content esgSubNav
In This List

Versartis, Aravive Biologics shift focus to ovarian cancer drug as merger closes

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Versartis, Aravive Biologics shift focus to ovarian cancer drug as merger closes

Versartis Inc. has completed its merger with Aravive Biologics Inc. following stockholder approval Oct. 5.

The combined company, which will operate as Aravive Inc., will focus on the development of cancer therapies. President and CEO Jay Shepard said in an Oct. 15 statement that the newly formed Aravive will initially focus on developing its lead drug candidate AVB-S6-500 as a potential treatment of patients with platinum-resistant ovarian cancer. The therapy was granted fast track status by the U.S. Food and Drug Administration in August.

Aravive's common shares will trade on the Nasdaq Global Select Market under the ARAV symbol beginning Oct. 16.

In addition to the closure of the merger, the company will implement a 1-for-6 reverse split of its common shares which will reduce its outstanding common shares from 67.1 million to about 11.2 million.